Trial Profile
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2023
Price :
$35
*
At a glance
- Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms AMAC
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 17 Oct 2023 Results assessing the transcription profile of patients with ulcerative colitis who respond to placebo or mirikizumab versus non-responders and build a model that can predict response in patients with ulcerative colitis, presented at the 31st United European Gastroenterology Week.
- 23 Aug 2023 Results from NCT02589665, NCT03518086 and NCT03524092, evaluating Mirikizumab pharmacokinetics in patients with Moderately to Severely Active Ulcerative Colitis, published in the Clinical Pharmacokinetics
- 09 May 2023 Results of pooled analysis from three studies(NCT02589665, NCT03518086 and NCT03524092) assessing Mirikizumab pharmacokinetics and exposure response relationships in patients with moderately to severely active ulcerative colitis presented at the Digestive Disease Week 2023